Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Breakthough stem cell therapy could reverse chronic canine illness
Doctors already use stem cells to fight some forms of cancer and blood-related conditions in humans.
Study paves the way to new therapies and potenatial cures.

Researchers in Japan have devised a novel method to induce stem cell generation from dog blood samples.

Scientists at Osaka Prefecture University hope to use the technique to advance regenerative therapies in veterinary medicine. This could mean that vets may one day be able to reverse conditions in dogs previously thought to be incurable.

Doctors already use stem cells to fight some forms of cancer and blood-related conditions in humans, such as leukaemia and lymphoma. Stem cells can differentiate and mature into many specialised cell types, known as 'pluripotency'.

By transplanting stem cells and guiding their differentiation into desired cell types, doctors can repair damaged tissue and reverse the course of complex conditions. But while this technique has been widely studied in humans, it has not been thoroughly explored in dogs.

In this study, the scientists worked on isolating induced pluripotent stem cells (iPSCs) from canine blood samples. iPSCs are a type of stem cell that can be “programmed” from a developed (or “differentiated”) cell by introducing a specific set of genes into them. 

These genes code for proteins called 'transcription factors' that induce the change from a 'differentiated' to a 'pluripotent' stem cell, which then can mature into various cell types. The scientists found that iPSCs can proliferate very rapidly, thereby providing a reliable supply of suitable stem cells for regenerative therapies.

Study leader Shingo Hatoya, an Associate Professor from Osaka Prefecture University, said: “We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells”. He added that the findings have great significance for veterinary medicine and that, one day, “it may be possible to perform regenerative medicinal treatments in dogs.” 

Interestingly, the study authors believe that further research into regenerative therapies for canines might have some ripple effects for human medicine. Professor Hatoya added: "Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases." 

Translating findings from one field to another could pave the way to new treatments or even cures for some infections that continue to plague humanity. The findings are published in the journal Stem Cells and Development

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.